Related Experiment Videos
Antibiotic prophylaxis influences cardiovascular stability in complicated surgery
1Institute of Theoretical Surgery, Philipps-University, 35033, Marburg, Germany. celik@mailer.uni-marburg.de
Summary
Antibiotic prophylaxis can affect cardiovascular stability during surgery. A pig model showed cefuroxime/metronidazole reduced histamine release reactions compared to co-amoxiclav, suggesting potential benefits in complex surgical scenarios.
Area of Science:
- Veterinary Medicine
- Surgical Research
- Pharmacology
Background:
- Perioperative cardiovascular instability is a concern with antibiotic prophylaxis.
- A need exists to evaluate the impact of common antibiotic combinations on cardiovascular stability during major surgery.
Purpose of the Study:
- To compare the effects of co-amoxiclav and cefuroxime/metronidazole on cardiovascular stability during major surgery using a novel clinic modelling randomised trial (CMRT) in pigs.
- To assess histamine release reactions as a marker for cardiovascular instability.
Main Methods:
- A randomized controlled trial in 30 pigs, divided into placebo, co-amoxiclav, and cefuroxime/metronidazole groups.
- Simulated surgical complications including blood loss and induced anaphylactoid reactions.
- Monitored cardiovascular changes and plasma histamine concentrations.
Main Results:
- Co-amoxiclav group showed increased plasma histamine post-bleeding.
- While overall histamine release and cardiovascular changes were similar post-resuscitation, the incidence of histamine release reactions differed significantly.
- Cefuroxime/metronidazole group had a significantly lower incidence (2/10) of histamine release reactions compared to controls (8/10) and co-amoxiclav (6/10).
Conclusions:
- The clinic modelling randomised trial (CMRT) is a stable and reproducible model for investigating antibiotic effects.
- Antibiotic prophylaxis can influence the body's response to surgical complications like bleeding and fluid resuscitation.
- Complex animal models are crucial for evaluating new antibiotics before clinical trials.